Impact of alemtuzumab on health-related quality of life over 6 years in CARE-MS II trial extension patients with relapsing-remitting multiple sclerosis

por Arroyo, Rafael, Bury, Denise P, Guo, Jennifer D, Margolin, David H, Melanson, Maria, Daizadeh, Nadia, Cella, David
Publicado 2019

Efficacy and Safety of Alemtuzumab in Patients of African Descent with Relapsing-Remitting Multiple Sclerosis: 8-Year Follow-up of CARE-MS I and II (TOPAZ Study)

por Okai, Annette F., Amezcua, Lilyana, Berkovich, Regina R., Chinea, Angel R., Edwards, Keith R., Steingo, Brian, Walker, Aljoeson, Jacobs, Alan K., Daizadeh, Nadia, Williams, Mitzi J.
Publicado 2019

Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma

por Busse, William W., Paggiaro, Pierluigi, Muñoz, Xavier, Casale, Thomas B., Castro, Mario, Canonica, G. Walter, Douglass, Jo A., Tohda, Yuji, Daizadeh, Nadia, Ortiz, Benjamin, Pandit-Abid, Nami
Publicado 2021

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

por Adachi, Jonathan D., Bone, Henry G., Daizadeh, Nadia S., Dakin, Paula, Papapoulos, Socrates, Hadji, Peyman, Recknor, Chris, Bolognese, Michael A., Wang, Andrea, Lin, Celia J. F., Wagman, Rachel B., Ferrari, Serge
Publicado 2017

Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab

por Wiendl, Heinz, Carraro, Matthew, Comi, Giancarlo, Izquierdo, Guillermo, Kim, Ho Jin, Sharrack, Basil, Tornatore, Carlo, Daizadeh, Nadia, Chung, Luke, Jacobs, Alan K., Hogan, Richard J., Wychowski, Linda V., Van Wijmeersch, Bart
Publicado 2019

Proportion of alemtuzumab-treated patients converting from relapsing-remitting multiple sclerosis to secondary progressive multiple sclerosis over 6 years

por Horáková, Dana, Boster, Aaron, Bertolotto, Antonio, Freedman, Mark S, Firmino*, Isabel, Cavalier, Steven J, Jacobs*, Alan K, Thangavelu*, Karthinathan, Daizadeh, Nadia, Poole*, Elizabeth M, Baker, Darren P, Margolin*, David H, Ziemssen, Tjalf
Publicado 2020

Dupilumab efficacy and safety in patients with asthma and blood eosinophils ≥500 cells·µL(−1)

por Rabe, Klaus F., Pavord, Ian D., Castro, Mario, Wechsler, Michael E., Daizadeh, Nadia, Kapoor, Upender, Ortiz, Benjamin, Radwan, Amr, Johnson, Robert R., Rowe, Paul J., Deniz, Yamo, Jacob-Nara, Juby A.
Publicado 2022

Dupilumab Efficacy in Patients with Type 2 Asthma with and without Elevated Blood Neutrophils

por Bleecker, Eugene R., Panettieri, Reynold A., Lugogo, Njira L., Corren, Jonathan, Daizadeh, Nadia, Jacob-Nara, Juby A., Deniz, Yamo, Rowe, Paul J., Khodzhayev, Angela, Soler, Xavier, Ferro, Thomas J., Hansen, Christopher N.
Publicado 2023

Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds

por Chuang, Chien‐Chia, Guillemin, Isabelle, Bachert, Claus, Lee, Stella E., Hellings, Peter W., Fokkens, Wytske J., Duverger, Nicolas, Fan, Chunpeng, Daizadeh, Nadia, Amin, Nikhil, Mannent, Leda P., Khan, Asif H., Kamat, Siddhesh
Publicado 2021

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

por Schemitsch, Emil H., Miclau, Theodore, Karachalios, Theofilos, Nowak, Lauren L., Sancheti, Parag, Poolman, Rudolf W., Caminis, John, Daizadeh, Nadia, Dent-Acosta, Ricardo E., Egbuna, Ogo, Chines, Arkadi, Maddox, Judy, Grauer, Andreas, Bhandari, Mohit
Publicado 2020

Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized pl...

por Mullol, Joaquim, Laidlaw, Tanya M., Bachert, Claus, Mannent, Leda P., Canonica, G. Walter, Han, Joseph K., Maspero, Jorge F., Picado, Cesar, Daizadeh, Nadia, Ortiz, Benjamin, Li, Yongtao, Ruddy, Marcella, Laws, Elizabeth, Amin, Nikhil
Publicado 2021

Dupilumab reduced impact of severe exacerbations on lung function in patients with moderate‐to‐severe type 2 asthma

por Papi, Alberto, Corren, Jonathan, Castro, Mario, Domingo, Christian, Rogers, Linda, Chapman, Kenneth R., Jackson, Daniel J., Daizadeh, Nadia, Pandit‐Abid, Nami, Gall, Rebecca, Jacob‐Nara, Juby A., Rowe, Paul J., Deniz, Yamo, Ortiz, Benjamin
Publicado 2022

Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study

por Wray, Sibyl, Havrdova, Eva, Snydman, David R, Arnold, Douglas L, Cohen, Jeffrey A, Coles, Alasdair J, Hartung, Hans-Peter, Selmaj, Krzysztof W, Weiner, Howard L, Daizadeh, Nadia, Margolin, David H, Chirieac, Madalina C, Compston, D Alastair S
Publicado 2018

Improvement in Lung Function with Dupilumab Does Not Predict Its Effects on Reducing Asthma Exacerbation

por Hanania, Nicola A, Maspero, Jorge F, Halpin, David M G, Jackson, David J, Panettieri, Reynold A, Castro, Mario, Domingo, Christian, Daizadeh, Nadia, Gall, Rebecca, Jacob-Nara, Juby A, Ortiz, Benjamin, Djandji, Michel, Rowe, Paul J, Deniz, Yamo
Publicado 2022

Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223

por Steingo, Brian, Al Malik, Yaser, Bass, Ann D., Berkovich, Regina, Carraro, Matthew, Fernández, Óscar, Ionete, Carolina, Massacesi, Luca, Meuth, Sven G., Mitsikostas, Dimos D., Pardo, Gabriel, Simm, Renata Faria, Traboulsee, Anthony, Choudhry, Zia, Daizadeh, Nadia, Compston, D. Alastair S.
Publicado 2020

Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization

por Corren, Jonathan, Jackson, David J, Casale, Thomas B, Borish, Larry, Rabe, Klaus F, Busse, William W, Maspero, Jorge F, Jackson, Daniel J, Daizadeh, Nadia, Altincatal, Arman, Radwan, Amr, Khodzhayev, Angela, Djandji, Michel, Jacob-Nara, Juby A, Rowe, Paul J, Deniz, Yamo
Publicado 2023

Efficacy and safety of alemtuzumab over 6 years: final results of the 4-year CARE-MS extension trial

por Coles, Alasdair J., Arnold, Douglas L., Bass, Ann D., Boster, Aaron L., Compston, D. Alastair S., Fernández, Óscar, Havrdová, Eva Kubala, Nakamura, Kunio, Traboulsee, Anthony, Ziemssen, Tjalf, Jacobs, Alan, Margolin, David H., Huang, Xiaobi, Daizadeh, Nadia, Chirieac, Madalina C., Selmaj, Krzysztof W.
Publicado 2021

Sustained reduction of serum neurofilament light chain over 7 years by alemtuzumab in early relapsing–remitting MS

por Kuhle, Jens, Daizadeh, Nadia, Benkert, Pascal, Maceski, Aleksandra, Barro, Christian, Michalak, Zuzanna, Sormani, Maria Pia, Godin, Jean, Shankara, Srinivas, Samad, Tarek A, Jacobs, Alan, Chung, Luke, Rӧsch, Nora, Kaiser, Carina, Mitchell, Colin P, Leppert, David, Havari, Evis, Kappos, Ludwig
Publicado 2021

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of th...

por Bertolotto, Antonio, Arroyo, Rafael, Celius, Elisabeth G., Comi, Giancarlo, Havrdova, Eva Kubala, Honeycutt, William David, Hunter, Samuel F., Izquierdo, Guillermo, Kornek, Barbara, Miller, Tamara, Mitsikostas, Dimos D., Singer, Barry A., Ziemssen, Tjalf, Chung, Luke, Daizadeh, Nadia, Afsar, Salman, Hashemi, Lobat, Senior, Peter
Publicado 2020

Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of th...

por Hunter, Samuel F., Aburashed, Rany A., Alroughani, Raed, Chan, Andrew, Dive, Dominique, Eichau, Sara, Kantor, Daniel, Kim, Ho Jin, Lycke, Jan, Macdonell, Richard A. L., Pozzilli, Carlo, Scott, Thomas, Sharrack, Basil, Wiendl, Heinz, Chung, Luke, Daizadeh, Nadia, Baker, Darren P., Vermersch, Patrick
Publicado 2021